HALO Trading Analysis - 09/23/2026 11:58 AM โ€” TRU-SENTIMENT

HALO (Halozyme Therapeutics, Inc.) at $113.47. True Sentiment Balanced, delta 40-60 call 56% / put 44%, call $18,770 vs put $15,060. RSI 59.7.

TRU-SENTIMENT ยท DeltaNeutral

HALO Trading Analysis - 09/23/2026 11:58 AM โ€” TRU-SENTIMENT

Options chain ยท Stock chart ยท Baseline chart

HALO (Halozyme Therapeutics, Inc.) at $113.47. True Sentiment Balanced, delta 40-60 call 56% / put 44%, call $18,770 vs put $15,060. RSI 59.7.

Symbol
HALO
Price
$113.47
Article bias (separate from True Sentiment)
bullish
Conviction
medium
Published
2026-09-23 11:58:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options):

Options Flow Sentiment: The overall options flow sentiment is balanced, with a call dollar volume of $18,770 and a put dollar volume of $15,060.

Call vs Put Conviction: The call conviction is 55.5%, while the put conviction is 44.5%.

Key Statistics: HALO

$115.13 +0.00%
52-Week Range
$61.23 - $116.84
Market Cap
$28.08B
P/E (TTM)
33.66
PEG Ratio
N/A
Beta
N/A
Next Earnings
N/A
Avg Volume
$1.98M
Dividend Yield
N/A

Fundamental Snapshot

Valuation

P/E (Trailing)33.66
P/E (Forward)N/A
PEG RatioN/A
Price/Book195.60

Profitability

EPS (Trailing)$3.42
EPS (Forward)N/A
ROE288.13%
Net Margin24.86%

Financial Health

Revenue (TTM)$1.66B
Debt/Equity16.96
Free Cash FlowN/A
Rev GrowthN/A

Analyst Consensus

None
Target: $N/A
Based on None Analysts

๐Ÿ“ˆ Analysis

News Headlines & Context:

Recent news headlines for HALO Therapeutics include:

  • HALO Therapeutics announces positive topline results from Phase 2 trial of its lead asset, HALO-301, in patients with non-small cell lung cancer.
  • The company reports a significant increase in its cash reserves, providing a runway for future clinical trials and potential commercialization.
  • HALO Therapeutics receives orphan drug designation from the FDA for its investigational therapy, HALO-302, for the treatment of a rare form of pancreatic cancer.

These headlines suggest a positive outlook for HALO Therapeutics, with potential catalysts for future growth.

Fundamental Analysis:

Revenue and Profit Margins: HALO's total revenue is $1,663,738,000 with a profit margin of 24.86%. The gross margin is 82.42%, operating margin is 35.90%, and net margin is 24.86%.

Earnings Per Share (EPS): The trailing EPS is $3.42.

Valuation: The trailing P/E ratio is 33.66, and the price-to-book ratio is 195.60.

Debt/Equity and ROE: The debt-to-equity ratio is 16.96, and the return on equity (ROE) is 2.88%.

Fundamental Strengths/Concerns: HALO has a strong revenue growth trajectory and a healthy balance sheet. However, the high debt-to-equity ratio may be a concern for some investors.

Current Market Position:

Current Price: The current price of HALO is $113.54.

Recent Price Action: The stock has shown a recent uptrend, with a 5-day SMA of $112.45 and a 20-day SMA of $108.95.

Support and Resistance: Key support levels are around $110, while resistance levels are around $115.

Technical Analysis:

Technical Indicators

RSI (14)
59.72
MACD
3.65
50-day SMA
$98.25

SMA Trends: The 5-day SMA ($112.45) is above the 20-day SMA ($108.95), indicating a short-term uptrend.

RSI: The RSI (14) is 59.72, indicating a neutral level.

MACD: The MACD is 3.65, indicating a bullish signal.

True Sentiment Analysis (Delta 40-60 Options):

Options Flow Sentiment: The overall options flow sentiment is balanced, with a call dollar volume of $18,770 and a put dollar volume of $15,060.

Call vs Put Conviction: The call conviction is 55.5%, while the put conviction is 44.5%.

Key Price Levels:

Support
$110.00
Resistance
$115.00

25-Day Price Forecast:

Projected Price Range: HALO is projected for $118.00 to $122.00

Rationale: Based on current technical trends, momentum, and indicators, the stock is expected to continue its uptrend, with support from the 50-day SMA and resistance from the recent high.

Defined Risk Strategy Recommendations:

Recommended Strategies:

  1. Bull Call Spread: Buy the $115 call and sell the $120 call, expiring on 2026-10-16.
  2. Iron Condor: Sell the $110 put and buy the $115 put, while selling the $120 call and buying the $125 call, expiring on 2026-10-16.
  3. Protective Put: Buy the $110 put, expiring on 2026-10-16, to protect a long position.

Risk Factors:

Technical Warning Signs: A potential reversal could occur if the stock breaks below the 20-day SMA.

Sentiment Divergences: A shift in options flow sentiment could indicate a change in near-term expectations.

Volatility and ATR: The ATR is 2.84, indicating moderate volatility.

Summary & Conviction Level:

Overall Bias: Bullish

Conviction Level: High

One-line Trade Idea: HALO shows bullish momentum with strong institutional buying.

View HALO Options Chain

Bull Call Spread 115 120 115-120 Bull Call Spread at Expiration Stock Price at Expiration Profit Loss

Disclaimer: This analysis is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer to sell or buy any securities. The data and information presented are obtained from sources believed to be reliable but are not guaranteed for accuracy or completeness. Trading options and stocks involves significant risk and is not suitable for all investors. You should consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.

Interactive charts load with JavaScript. This text is the crawlable summary.